Menu
Skip to content

Investors

Albireo Pharma is a clinical-stage company focused through its operating subsidiary on the development of therapies for orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is an ileal bile acid transporter (IBAT) inhibitor in development for pediatric cholestatic liver diseases, initially progressive familial intrahepatic cholestasis (PFIC). Albireo Pharma is headquartered in Boston, Massachusetts and its operating subsidiary is located in Gothenburg, Sweden.

NASDAQ: ALBO

$22.01 -0.62 (2.74%)
Day High: 22.74 Day Low:  21.63
Volume: 18,083 Market Cap:  $M

Delayed ~20 min., by eSignal. 4:00 PM ET on Sep 19, 2017

Events & Presentations

Sep 26, 2017 at 9:00 AM ET
Sep 27, 2017 at 3:25 PM ET

Albireo Corporate Backgrounder

Albireo Homepage